KEYMED BIO-B: INSIDE INFORMATION -EXCLUSIVE LICENSE AGREEMENTFOR CM512 AND CM536
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
KEYMED BIO-B: SIXTH AMENDED AND RESTATEDMEMORANDUM AND ARTICLES OF ASSOCIATION
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT RESULTS FROM AN EXPLORATORY CLINICAL STUDY OF CM313 IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA WERE RECENTLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPSACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTLONG-TERM EFFICACY AND SAFETY DATA FROM A PHASE IIICLINICAL TRIAL OF STAPOKIBART INJECTION AT THEEUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY(EAACI) CONGRESS 2024
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTTHE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OFCMG901 (AZD0901) AT THE ASCO ANNUAL MEETING 2024 BY WAY OFORAL PRESENTATION
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTSTAPOKIBART INJECTION INCLUDED IN THE PRIORITYREVIEW AND APPROVAL PROCEDURES FOR THE TREATMENTOF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF SEASONAL ALLERGIC RHINITIS ACCEPTEDBY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTPHASE III CLINICAL TRIAL OF STAPOKIBART INJECTIONFOR THE TREATMENT OF SEASONAL ALLERGICRHINITIS ACHIEVED PRIMARY ENDPOINTS
KEYMED BIO-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
KEYMED BIO-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
KEYMED BIO-B: FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTUPDATE ON THE LICENSE AGREEMENT WITHASTRAZENECA ON CMG901 (AZD0901)
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTSHARE PURCHASE PURSUANT TOTHE 2022 RESTRICTED SHARE UNIT SCHEME
No Data